APO Research
Talk to an analyst

APO RESEARCH · REPORT

Third-Party Drug Testing Administration service

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Third-Party Drug Testing Administration service Market Outlook and Growth Opportunities 2026

1 January 2026198 pages

Choose your research edition.

Industry ResearchThird-Party Drug Testing Administration service Industry Research Report 2026129 pages · $2,950 USDIndustry Growth & TrendsGlobal Third-Party Drug Testing Administration service Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Third-Party Drug Testing Administration service Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Third-Party Drug Testing Administration service Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Third-Party Drug Testing Administration service Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Third-Party Drug Testing Administration service market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Third-Party Drug Testing Administration service is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Third-Party Drug Testing Administration service is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Third-Party Drug Testing Administration service is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Third-Party Drug Testing Administration service market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Third-Party Drug Testing Administration service market include Lobdock, Info Cubic, Procom Testing, Midway, National Drug Screening, CO-OP Drug Testing, ADVANTAGECARE, CannAmm and Medway, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Third-Party Drug Testing Administration service market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Third-Party Drug Testing Administration service and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Third-Party Drug Testing Administration service revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Third-Party Drug Testing Administration service market.

Third-Party Drug Testing Administration service Segment by Company

Lobdock

Info Cubic

Procom Testing

Midway

National Drug Screening

CO-OP Drug Testing

ADVANTAGECARE

CannAmm

Medway

AMDT

WorkPlace Health

Global Verification Network

Mobile Medical Corporation

DRUG TESTING CORPORATION

Origin

Third-Party Drug Testing Administration service Segment by Type

Pre-Employment Drug Testing

Reasonable Suspicion Drug Testing

Random Drug Testing

Return-to-Duty Drug Testing

Post-Accident Drug Testing

Others

Third-Party Drug Testing Administration service Segment by Application

SMEs

Large Enterprise

Third-Party Drug Testing Administration service Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Third-Party Drug Testing Administration service status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Third-Party Drug Testing Administration service key companies, revenue, market share, and recent developments.

3. To split the Third-Party Drug Testing Administration service breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Third-Party Drug Testing Administration service market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Third-Party Drug Testing Administration service significant trends, drivers, influence factors in global and regions.

6. To analyze Third-Party Drug Testing Administration service competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Third-Party Drug Testing Administration service market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Third-Party Drug Testing Administration service and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Third-Party Drug Testing Administration service.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Third-Party Drug Testing Administration service industry.

Chapter 3: Detailed analysis of Third-Party Drug Testing Administration service company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Third-Party Drug Testing Administration service in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Third-Party Drug Testing Administration service in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Third-Party Drug Testing Administration service Industry Trends Table 2. Third-Party Drug Testing Administration service Industry Drivers Table 3. Third-Party Drug Testing Administration service Industry Opportunities and Challenges Table 4. Third-Party Drug Testing Administration service Industry Restraints Table 5. Global Third-Party Drug Testing Administration service Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Third-Party Drug Testing Administration service Revenue Share by Company (2021-2026) Table 7. Global Third-Party Drug Testing Administration service Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Third-Party Drug Testing Administration service Key Company Manufacturing Base & Headquarters Table 9. Global Third-Party Drug Testing Administration service Company, Product Type & Application Table 10. Global Third-Party Drug Testing Administration service Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Third-Party Drug Testing Administration service by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Pre-Employment Drug Testing Table 15. Significant Companies of Reasonable Suspicion Drug Testing Table 16. Significant Companies of Random Drug Testing Table 17. Significant Companies of Return-to-Duty Drug Testing Table 18. Significant Companies of Post-Accident Drug Testing Table 19. Significant Companies of Others Table 20. Global Third-Party Drug Testing Administration service Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 21. Global Third-Party Drug Testing Administration service Sales Value by Type (2021-2026) & (US$ Million) Table 22. Global Third-Party Drug Testing Administration service Sales Value by Type (2027-2032) & (US$ Million) Table 23. Global Third-Party Drug Testing Administration service Sales Value Share by Type (2021-2026) Table 24. Global Third-Party Drug Testing Administration service Sales Value Share by Type (2027-2032) Table 25. Significant Companies of SMEs Table 26. Significant Companies of Large Enterprise Table 27. Global Third-Party Drug Testing Administration service Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Third-Party Drug Testing Administration service Sales Value by Application (2021-2026) & (US$ Million) Table 29. Global Third-Party Drug Testing Administration service Sales Value by Application (2027-2032) & (US$ Million) Table 30. Global Third-Party Drug Testing Administration service Sales Value Share by Application (2021-2026) Table 31. Global Third-Party Drug Testing Administration service Sales Value Share by Application (2027-2032) Table 32. Global Third-Party Drug Testing Administration service Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Third-Party Drug Testing Administration service Sales Value by Region (2021-2026) & (US$ Million) Table 34. Global Third-Party Drug Testing Administration service Sales Value Share by Region (2021-2026) Table 35. Global Third-Party Drug Testing Administration service Sales Value by Region (2027-2032) & (US$ Million) Table 36. Global Third-Party Drug Testing Administration service Sales Value Share by Region (2027-2032) Table 37. Global Third-Party Drug Testing Administration service Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Third-Party Drug Testing Administration service Sales Value by Country (2021-2026) & (US$ Million) Table 39. Global Third-Party Drug Testing Administration service Sales Value Market Share by Country (2021-2026) Table 40. Global Third-Party Drug Testing Administration service Sales Value by Country (2027-2032) & (US$ Million) Table 41. Global Third-Party Drug Testing Administration service Sales Value Market Share by Country (2027-2032) Table 42. Lobdock Company Information Table 43. Lobdock Business Overview Table 44. Lobdock Third-Party Drug Testing Administration service Revenue (US$ Million) and Gross Margin (2021-2026) Table 45. Lobdock Third-Party Drug Testing Administration service Product Portfolio Table 46. Lobdock Recent Development Table 47. Info Cubic Company Information Table 48. Info Cubic Business Overview Table 49. Info Cubic Third-Party Drug Testing Administration service Revenue (US$ Million) and Gross Margin (2021-2026) Table 50. Info Cubic Third-Party Drug Testing Administration service Product Portfolio Table 51. Info Cubic Recent Development Table 52. Procom Testing Company Information Table 53. Procom Testing Business Overview Table 54. Procom Testing Third-Party Drug Testing Administration service Revenue (US$ Million) and Gross Margin (2021-2026) Table 55. Procom Testing Third-Party Drug Testing Administration service Product Portfolio Table 56. Procom Testing Recent Development Table 57. Midway Company Information Table 58. Midway Business Overview Table 59. Midway Third-Party Drug Testing Administration service Revenue (US$ Million) and Gross Margin (2021-2026) Table 60. Midway Third-Party Drug Testing Administration service Product Portfolio Table 61. Midway Recent Development Table 62. National Drug Screening Company Information Table 63. National Drug Screening Business Overview Table 64. National Drug Screening Third-Party Drug Testing Administration service Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. National Drug Screening Third-Party Drug Testing Administration service Product Portfolio Table 66. National Drug Screening Recent Development Table 67. CO-OP Drug Testing Company Information Table 68. CO-OP Drug Testing Business Overview Table 69. CO-OP Drug Testing Third-Party Drug Testing Administration service Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. CO-OP Drug Testing Third-Party Drug Testing Administration service Product Portfolio Table 71. CO-OP Drug Testing Recent Development Table 72. ADVANTAGECARE Company Information Table 73. ADVANTAGECARE Business Overview Table 74. ADVANTAGECARE Third-Party Drug Testing Administration service Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. ADVANTAGECARE Third-Party Drug Testing Administration service Product Portfolio Table 76. ADVANTAGECARE Recent Development Table 77. CannAmm Company Information Table 78. CannAmm Business Overview Table 79. CannAmm Third-Party Drug Testing Administration service Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. CannAmm Third-Party Drug Testing Administration service Product Portfolio Table 81. CannAmm Recent Development Table 82. Medway Company Information Table 83. Medway Business Overview Table 84. Medway Third-Party Drug Testing Administration service Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Medway Third-Party Drug Testing Administration service Product Portfolio Table 86. Medway Recent Development Table 87. AMDT Company Information Table 88. AMDT Business Overview Table 89. AMDT Third-Party Drug Testing Administration service Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. AMDT Third-Party Drug Testing Administration service Product Portfolio Table 91. AMDT Recent Development Table 92. WorkPlace Health Company Information Table 93. WorkPlace Health Business Overview Table 94. WorkPlace Health Third-Party Drug Testing Administration service Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. WorkPlace Health Third-Party Drug Testing Administration service Product Portfolio Table 96. WorkPlace Health Recent Development Table 97. Global Verification Network Company Information Table 98. Global Verification Network Business Overview Table 99. Global Verification Network Third-Party Drug Testing Administration service Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Global Verification Network Third-Party Drug Testing Administration service Product Portfolio Table 101. Global Verification Network Recent Development Table 102. Mobile Medical Corporation Company Information Table 103. Mobile Medical Corporation Business Overview Table 104. Mobile Medical Corporation Third-Party Drug Testing Administration service Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Mobile Medical Corporation Third-Party Drug Testing Administration service Product Portfolio Table 106. Mobile Medical Corporation Recent Development Table 107. DRUG TESTING CORPORATION Company Information Table 108. DRUG TESTING CORPORATION Business Overview Table 109. DRUG TESTING CORPORATION Third-Party Drug Testing Administration service Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. DRUG TESTING CORPORATION Third-Party Drug Testing Administration service Product Portfolio Table 111. DRUG TESTING CORPORATION Recent Development Table 112. Origin Company Information Table 113. Origin Business Overview Table 114. Origin Third-Party Drug Testing Administration service Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. Origin Third-Party Drug Testing Administration service Product Portfolio Table 116. Origin Recent Development Table 117. Research Programs/Design for This Report Table 118. Authors List of This Report Table 119. Secondary Sources Table 120. Primary Sources List of Figures Figure 1. Third-Party Drug Testing Administration service Product Image Figure 2. Global Third-Party Drug Testing Administration service Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Third-Party Drug Testing Administration service Market Size (2021-2032) & (US$ Million) Figure 4. Global Third-Party Drug Testing Administration service Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Pre-Employment Drug Testing Image Figure 8. Reasonable Suspicion Drug Testing Image Figure 9. Random Drug Testing Image Figure 10. Return-to-Duty Drug Testing Image Figure 11. Post-Accident Drug Testing Image Figure 12. Others Image Figure 13. Global Third-Party Drug Testing Administration service Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 14. Global Third-Party Drug Testing Administration service Sales Value Share 2021 VS 2025 VS 2032 Figure 15. Global Third-Party Drug Testing Administration service Sales Value Share by Type (2021-2032) Figure 16. SMEs Image Figure 17. Large Enterprise Image Figure 18. Global Third-Party Drug Testing Administration service Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Third-Party Drug Testing Administration service Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Third-Party Drug Testing Administration service Sales Value Share by Application (2021-2032) Figure 21. Global Third-Party Drug Testing Administration service Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 22. Global Third-Party Drug Testing Administration service Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 23. North America Third-Party Drug Testing Administration service Sales Value (2021-2032) & (US$ Million) Figure 24. North America Third-Party Drug Testing Administration service Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Europe Third-Party Drug Testing Administration service Sales Value (2021-2032) & (US$ Million) Figure 26. Europe Third-Party Drug Testing Administration service Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Asia-Pacific Third-Party Drug Testing Administration service Sales Value (2021-2032) & (US$ Million) Figure 28. Asia-Pacific Third-Party Drug Testing Administration service Sales Value Share by Country (%), 2025 VS 2032 Figure 29. South America Third-Party Drug Testing Administration service Sales Value (2021-2032) & (US$ Million) Figure 30. South America Third-Party Drug Testing Administration service Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Middle East & Africa Third-Party Drug Testing Administration service Sales Value (2021-2032) & (US$ Million) Figure 32. Middle East & Africa Third-Party Drug Testing Administration service Sales Value Share by Country (%), 2025 VS 2032 Figure 33. USA Third-Party Drug Testing Administration service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. USA Third-Party Drug Testing Administration service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. USA Third-Party Drug Testing Administration service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Canada Third-Party Drug Testing Administration service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Canada Third-Party Drug Testing Administration service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Canada Third-Party Drug Testing Administration service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Mexico Third-Party Drug Testing Administration service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Mexico Third-Party Drug Testing Administration service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Mexico Third-Party Drug Testing Administration service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Germany Third-Party Drug Testing Administration service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Germany Third-Party Drug Testing Administration service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Germany Third-Party Drug Testing Administration service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. France Third-Party Drug Testing Administration service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. France Third-Party Drug Testing Administration service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. France Third-Party Drug Testing Administration service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. U.K. Third-Party Drug Testing Administration service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. U.K. Third-Party Drug Testing Administration service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. U.K. Third-Party Drug Testing Administration service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Italy Third-Party Drug Testing Administration service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Italy Third-Party Drug Testing Administration service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Italy Third-Party Drug Testing Administration service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Spain Third-Party Drug Testing Administration service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Spain Third-Party Drug Testing Administration service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Spain Third-Party Drug Testing Administration service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Russia Third-Party Drug Testing Administration service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Russia Third-Party Drug Testing Administration service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Russia Third-Party Drug Testing Administration service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Netherlands Third-Party Drug Testing Administration service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Netherlands Third-Party Drug Testing Administration service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Netherlands Third-Party Drug Testing Administration service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Nordic Countries Third-Party Drug Testing Administration service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Nordic Countries Third-Party Drug Testing Administration service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Nordic Countries Third-Party Drug Testing Administration service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. China Third-Party Drug Testing Administration service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. China Third-Party Drug Testing Administration service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. China Third-Party Drug Testing Administration service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Japan Third-Party Drug Testing Administration service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Japan Third-Party Drug Testing Administration service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Japan Third-Party Drug Testing Administration service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. South Korea Third-Party Drug Testing Administration service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. South Korea Third-Party Drug Testing Administration service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. South Korea Third-Party Drug Testing Administration service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. India Third-Party Drug Testing Administration service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. India Third-Party Drug Testing Administration service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. India Third-Party Drug Testing Administration service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Australia Third-Party Drug Testing Administration service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Australia Third-Party Drug Testing Administration service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Australia Third-Party Drug Testing Administration service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Southeast Asia Third-Party Drug Testing Administration service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Southeast Asia Third-Party Drug Testing Administration service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Southeast Asia Third-Party Drug Testing Administration service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Brazil Third-Party Drug Testing Administration service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Brazil Third-Party Drug Testing Administration service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Brazil Third-Party Drug Testing Administration service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Argentina Third-Party Drug Testing Administration service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Argentina Third-Party Drug Testing Administration service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Argentina Third-Party Drug Testing Administration service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Chile Third-Party Drug Testing Administration service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Chile Third-Party Drug Testing Administration service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Chile Third-Party Drug Testing Administration service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Colombia Third-Party Drug Testing Administration service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Colombia Third-Party Drug Testing Administration service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Colombia Third-Party Drug Testing Administration service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Peru Third-Party Drug Testing Administration service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Peru Third-Party Drug Testing Administration service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Peru Third-Party Drug Testing Administration service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Third-Party Drug Testing Administration service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Saudi Arabia Third-Party Drug Testing Administration service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Saudi Arabia Third-Party Drug Testing Administration service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Israel Third-Party Drug Testing Administration service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Israel Third-Party Drug Testing Administration service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Israel Third-Party Drug Testing Administration service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. UAE Third-Party Drug Testing Administration service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. UAE Third-Party Drug Testing Administration service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. UAE Third-Party Drug Testing Administration service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Turkey Third-Party Drug Testing Administration service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Turkey Third-Party Drug Testing Administration service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Turkey Third-Party Drug Testing Administration service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Iran Third-Party Drug Testing Administration service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Iran Third-Party Drug Testing Administration service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Iran Third-Party Drug Testing Administration service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Egypt Third-Party Drug Testing Administration service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Egypt Third-Party Drug Testing Administration service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Egypt Third-Party Drug Testing Administration service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Years Considered Figure 118. Research Process Figure 119. Key Executives Interviewed

Scope & coverage.

Types
  • Pre-Employment Drug Testing
  • Reasonable Suspicion Drug Testing
  • Random Drug Testing
  • Return-to-Duty Drug Testing
  • Post-Accident Drug Testing
  • Others
Applications
  • SMEs
  • Large Enterprise
Companies covered
  • Lobdock
  • Info Cubic
  • Procom Testing
  • Midway
  • National Drug Screening
  • CO-OP Drug Testing
  • ADVANTAGECARE
  • CannAmm
  • Medway
  • AMDT
  • WorkPlace Health
  • Global Verification Network
  • Mobile Medical Corporation
  • DRUG TESTING CORPORATION
  • Origin

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Third-Party Drug Testing Administration service Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Third-Party Drug Testing Administration service Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Third-Party Drug Testing Administration service Market Dynamics
  1. 2.1 Third-Party Drug Testing Administration service Industry Trends
  2. 2.2 Third-Party Drug Testing Administration service Industry Drivers
  3. 2.3 Third-Party Drug Testing Administration service Industry Opportunities and Challenges
  4. 2.4 Third-Party Drug Testing Administration service Industry Restraints
3 Third-Party Drug Testing Administration service Market by Company
  1. 3.1 Global Third-Party Drug Testing Administration service Company Revenue Ranking in 2025
  2. 3.2 Global Third-Party Drug Testing Administration service Revenue by Company (2021-2026)
  3. 3.3 Global Third-Party Drug Testing Administration service Company Ranking (2024-2026)
  4. 3.4 Global Third-Party Drug Testing Administration service Company Manufacturing Base and Headquarters
  5. 3.5 Global Third-Party Drug Testing Administration service Company Product Type and Application
  6. 3.6 Global Third-Party Drug Testing Administration service Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Third-Party Drug Testing Administration service Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Third-Party Drug Testing Administration service Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Third-Party Drug Testing Administration service Market by Type
  1. 4.1 Third-Party Drug Testing Administration service Type Introduction
  2. 4.1.1 Pre-Employment Drug Testing
  3. 4.1.2 Reasonable Suspicion Drug Testing
  4. 4.1.3 Random Drug Testing
  5. 4.1.4 Return-to-Duty Drug Testing
  6. 4.1.5 Post-Accident Drug Testing
  7. 4.1.6 Others
  8. 4.2 Global Third-Party Drug Testing Administration service Sales Value by Type
  9. 4.2.1 Global Third-Party Drug Testing Administration service Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Third-Party Drug Testing Administration service Sales Value by Type (2021-2032)
  11. 4.2.3 Global Third-Party Drug Testing Administration service Sales Value Share by Type (2021-2032)
5 Third-Party Drug Testing Administration service Market by Application
  1. 5.1 Third-Party Drug Testing Administration service Application Introduction
  2. 5.1.1 SMEs
  3. 5.1.2 Large Enterprise
  4. 5.2 Global Third-Party Drug Testing Administration service Sales Value by Application
  5. 5.2.1 Global Third-Party Drug Testing Administration service Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Third-Party Drug Testing Administration service Sales Value by Application (2021-2032)
  7. 5.2.3 Global Third-Party Drug Testing Administration service Sales Value Share by Application (2021-2032)
6 Third-Party Drug Testing Administration service Regional Value Analysis
  1. 6.1 Global Third-Party Drug Testing Administration service Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Third-Party Drug Testing Administration service Sales Value by Region (2021-2032)
  3. 6.2.1 Global Third-Party Drug Testing Administration service Sales Value by Region: 2021-2026
  4. 6.2.2 Global Third-Party Drug Testing Administration service Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Third-Party Drug Testing Administration service Sales Value (2021-2032)
  7. 6.3.2 North America Third-Party Drug Testing Administration service Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Third-Party Drug Testing Administration service Sales Value (2021-2032)
  10. 6.4.2 Europe Third-Party Drug Testing Administration service Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Third-Party Drug Testing Administration service Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Third-Party Drug Testing Administration service Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Third-Party Drug Testing Administration service Sales Value (2021-2032)
  16. 6.6.2 South America Third-Party Drug Testing Administration service Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Third-Party Drug Testing Administration service Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Third-Party Drug Testing Administration service Sales Value Share by Country, 2025 VS 2032
7 Third-Party Drug Testing Administration service Country-level Value Analysis
  1. 7.1 Global Third-Party Drug Testing Administration service Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Third-Party Drug Testing Administration service Sales Value by Country (2021-2032)
  3. 7.2.1 Global Third-Party Drug Testing Administration service Sales Value by Country (2021-2026)
  4. 7.2.2 Global Third-Party Drug Testing Administration service Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Third-Party Drug Testing Administration service Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Third-Party Drug Testing Administration service Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Third-Party Drug Testing Administration service Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Third-Party Drug Testing Administration service Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Third-Party Drug Testing Administration service Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Third-Party Drug Testing Administration service Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Third-Party Drug Testing Administration service Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Third-Party Drug Testing Administration service Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Third-Party Drug Testing Administration service Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Third-Party Drug Testing Administration service Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Third-Party Drug Testing Administration service Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Third-Party Drug Testing Administration service Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Third-Party Drug Testing Administration service Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Third-Party Drug Testing Administration service Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Third-Party Drug Testing Administration service Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Third-Party Drug Testing Administration service Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Third-Party Drug Testing Administration service Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Third-Party Drug Testing Administration service Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Third-Party Drug Testing Administration service Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Third-Party Drug Testing Administration service Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Third-Party Drug Testing Administration service Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Third-Party Drug Testing Administration service Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Third-Party Drug Testing Administration service Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Third-Party Drug Testing Administration service Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Third-Party Drug Testing Administration service Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Third-Party Drug Testing Administration service Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Third-Party Drug Testing Administration service Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Third-Party Drug Testing Administration service Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Third-Party Drug Testing Administration service Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Third-Party Drug Testing Administration service Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Third-Party Drug Testing Administration service Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Third-Party Drug Testing Administration service Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Third-Party Drug Testing Administration service Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Third-Party Drug Testing Administration service Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Third-Party Drug Testing Administration service Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Third-Party Drug Testing Administration service Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Third-Party Drug Testing Administration service Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Third-Party Drug Testing Administration service Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Third-Party Drug Testing Administration service Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Third-Party Drug Testing Administration service Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Third-Party Drug Testing Administration service Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Third-Party Drug Testing Administration service Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Third-Party Drug Testing Administration service Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Third-Party Drug Testing Administration service Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Third-Party Drug Testing Administration service Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Third-Party Drug Testing Administration service Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Third-Party Drug Testing Administration service Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Third-Party Drug Testing Administration service Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Third-Party Drug Testing Administration service Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Third-Party Drug Testing Administration service Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Third-Party Drug Testing Administration service Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Third-Party Drug Testing Administration service Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Third-Party Drug Testing Administration service Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Third-Party Drug Testing Administration service Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Third-Party Drug Testing Administration service Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Third-Party Drug Testing Administration service Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Third-Party Drug Testing Administration service Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Third-Party Drug Testing Administration service Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Third-Party Drug Testing Administration service Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Third-Party Drug Testing Administration service Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Third-Party Drug Testing Administration service Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Third-Party Drug Testing Administration service Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Third-Party Drug Testing Administration service Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Third-Party Drug Testing Administration service Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Third-Party Drug Testing Administration service Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Third-Party Drug Testing Administration service Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Third-Party Drug Testing Administration service Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Third-Party Drug Testing Administration service Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Third-Party Drug Testing Administration service Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Third-Party Drug Testing Administration service Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Third-Party Drug Testing Administration service Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Third-Party Drug Testing Administration service Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Third-Party Drug Testing Administration service Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Third-Party Drug Testing Administration service Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Third-Party Drug Testing Administration service Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Third-Party Drug Testing Administration service Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Third-Party Drug Testing Administration service Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Third-Party Drug Testing Administration service Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Third-Party Drug Testing Administration service Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Third-Party Drug Testing Administration service Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Third-Party Drug Testing Administration service Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Third-Party Drug Testing Administration service Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Third-Party Drug Testing Administration service Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Third-Party Drug Testing Administration service Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Lobdock
  2. 8.1.1 Lobdock Company Information
  3. 8.1.2 Lobdock Business Overview
  4. 8.1.3 Lobdock Third-Party Drug Testing Administration service Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Lobdock Third-Party Drug Testing Administration service Product Portfolio
  6. 8.1.5 Lobdock Recent Developments
  7. 8.2 Info Cubic
  8. 8.2.1 Info Cubic Company Information
  9. 8.2.2 Info Cubic Business Overview
  10. 8.2.3 Info Cubic Third-Party Drug Testing Administration service Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Info Cubic Third-Party Drug Testing Administration service Product Portfolio
  12. 8.2.5 Info Cubic Recent Developments
  13. 8.3 Procom Testing
  14. 8.3.1 Procom Testing Company Information
  15. 8.3.2 Procom Testing Business Overview
  16. 8.3.3 Procom Testing Third-Party Drug Testing Administration service Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Procom Testing Third-Party Drug Testing Administration service Product Portfolio
  18. 8.3.5 Procom Testing Recent Developments
  19. 8.4 Midway
  20. 8.4.1 Midway Company Information
  21. 8.4.2 Midway Business Overview
  22. 8.4.3 Midway Third-Party Drug Testing Administration service Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Midway Third-Party Drug Testing Administration service Product Portfolio
  24. 8.4.5 Midway Recent Developments
  25. 8.5 National Drug Screening
  26. 8.5.1 National Drug Screening Company Information
  27. 8.5.2 National Drug Screening Business Overview
  28. 8.5.3 National Drug Screening Third-Party Drug Testing Administration service Revenue and Gross Margin (2021-2026)
  29. 8.5.4 National Drug Screening Third-Party Drug Testing Administration service Product Portfolio
  30. 8.5.5 National Drug Screening Recent Developments
  31. 8.6 CO-OP Drug Testing
  32. 8.6.1 CO-OP Drug Testing Company Information
  33. 8.6.2 CO-OP Drug Testing Business Overview
  34. 8.6.3 CO-OP Drug Testing Third-Party Drug Testing Administration service Revenue and Gross Margin (2021-2026)
  35. 8.6.4 CO-OP Drug Testing Third-Party Drug Testing Administration service Product Portfolio
  36. 8.6.5 CO-OP Drug Testing Recent Developments
  37. 8.7 ADVANTAGECARE
  38. 8.7.1 ADVANTAGECARE Company Information
  39. 8.7.2 ADVANTAGECARE Business Overview
  40. 8.7.3 ADVANTAGECARE Third-Party Drug Testing Administration service Revenue and Gross Margin (2021-2026)
  41. 8.7.4 ADVANTAGECARE Third-Party Drug Testing Administration service Product Portfolio
  42. 8.7.5 ADVANTAGECARE Recent Developments
  43. 8.8 CannAmm
  44. 8.8.1 CannAmm Company Information
  45. 8.8.2 CannAmm Business Overview
  46. 8.8.3 CannAmm Third-Party Drug Testing Administration service Revenue and Gross Margin (2021-2026)
  47. 8.8.4 CannAmm Third-Party Drug Testing Administration service Product Portfolio
  48. 8.8.5 CannAmm Recent Developments
  49. 8.9 Medway
  50. 8.9.1 Medway Company Information
  51. 8.9.2 Medway Business Overview
  52. 8.9.3 Medway Third-Party Drug Testing Administration service Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Medway Third-Party Drug Testing Administration service Product Portfolio
  54. 8.9.5 Medway Recent Developments
  55. 8.10 AMDT
  56. 8.10.1 AMDT Company Information
  57. 8.10.2 AMDT Business Overview
  58. 8.10.3 AMDT Third-Party Drug Testing Administration service Revenue and Gross Margin (2021-2026)
  59. 8.10.4 AMDT Third-Party Drug Testing Administration service Product Portfolio
  60. 8.10.5 AMDT Recent Developments
  61. 8.11 WorkPlace Health
  62. 8.11.1 WorkPlace Health Company Information
  63. 8.11.2 WorkPlace Health Business Overview
  64. 8.11.3 WorkPlace Health Third-Party Drug Testing Administration service Revenue and Gross Margin (2021-2026)
  65. 8.11.4 WorkPlace Health Third-Party Drug Testing Administration service Product Portfolio
  66. 8.11.5 WorkPlace Health Recent Developments
  67. 8.12 Global Verification Network
  68. 8.12.1 Global Verification Network Company Information
  69. 8.12.2 Global Verification Network Business Overview
  70. 8.12.3 Global Verification Network Third-Party Drug Testing Administration service Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Global Verification Network Third-Party Drug Testing Administration service Product Portfolio
  72. 8.12.5 Global Verification Network Recent Developments
  73. 8.13 Mobile Medical Corporation
  74. 8.13.1 Mobile Medical Corporation Company Information
  75. 8.13.2 Mobile Medical Corporation Business Overview
  76. 8.13.3 Mobile Medical Corporation Third-Party Drug Testing Administration service Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Mobile Medical Corporation Third-Party Drug Testing Administration service Product Portfolio
  78. 8.13.5 Mobile Medical Corporation Recent Developments
  79. 8.14 DRUG TESTING CORPORATION
  80. 8.14.1 DRUG TESTING CORPORATION Company Information
  81. 8.14.2 DRUG TESTING CORPORATION Business Overview
  82. 8.14.3 DRUG TESTING CORPORATION Third-Party Drug Testing Administration service Revenue and Gross Margin (2021-2026)
  83. 8.14.4 DRUG TESTING CORPORATION Third-Party Drug Testing Administration service Product Portfolio
  84. 8.14.5 DRUG TESTING CORPORATION Recent Developments
  85. 8.15 Origin
  86. 8.15.1 Origin Company Information
  87. 8.15.2 Origin Business Overview
  88. 8.15.3 Origin Third-Party Drug Testing Administration service Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Origin Third-Party Drug Testing Administration service Product Portfolio
  90. 8.15.5 Origin Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst